Coherus BioSciences Q3 Adj. EPS $(0.20) Beats $(0.22) Estimate, Sales $14.274M Miss $16.005M Estimate

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.22) by 9.09 percent. This is a 39.39 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $14.274 million which missed the analyst consensus estimate of $16.005 million by 10.81 percent. This is a 23.36 percent increase over sales of $11.571 million the same period last year.